Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report
01 - Pre-Meeting Briefing prepared by NICE
02 - Submission from the technology manufacturer – Celgene
03 - NICE request to the manufacturer for clarification on their submission
04 - Manufacturer clarification response
05 - Consultee submission – Leukaemia CARE & MDS (joint submission)
06 - Consultee submission – Royal College of Physicians Submission
07 - Clinical expert personal perspective – Bowen
08 - Patient expert personal perspective – Pirilla
09 - Patient expert personal perspective – Taylor
10 - Evidence Review Group report prepared by Kleijnen systematic reviews
11 - Manufacturer factual accuracy check of Evidence Review Group report
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report
11 July 2013 (8.67 Mb 4 sec) |
This page was last updated: 11 July 2013